Press Releases

Date Title and Summary
Toggle Summary Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
- Royal Brisbane and Women's Hospital acquisition is intended to expand access to potentially life-saving radiotherapy treatments to more patients - Hospital was the first in Australia to invest in the TomoTherapy® helical radiotherapy delivery platform and is now the first to secure the latest
Toggle Summary Accuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-term Heart and Lung Functionality
- Phase III, randomized controlled trial results highlight patient reported outcomes at 10 years'follow-up - TomoTherapy delivered hypofractionated radiotherapy was superior to conventional radiotherapy in maintaining patients' heart and lung functioning, enabling them to more easily perform daily
Toggle Summary Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SUNNYVALE, Calif. , Feb. 7, 2022 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference , which takes place February 15-17, 2022 .
Toggle Summary Accuray Reports Fiscal 2022 Second Quarter Financial Results
Record Revenue For Second Quarter Fiscal 2022 SUNNYVALE, Calif. , Jan. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2022 ended December 31, 2021 .     Second Quarter Fiscal 2022 Summary Record net revenue of $116.3
Toggle Summary Accuray to Report Second Quarter Fiscal 2022 Financial Results on January 26, 2022
SUNNYVALE, Calif. , Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022. Management will host a conference call to review the
Toggle Summary Accuray CyberKnife® Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve
- Trigeminal neuralgia, a persistent neurological disorder, is described by some patients as the most excruciating pain human beings can experience(1) - The approval expands global patient access to the CyberKnife System, an effective, non-invasive treatment alternative to surgery SUNNYVALE, Calif.
Toggle Summary Accuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery
7,000 Patient Single Institution Analysis Shows Safety, Versatility and Increasing Use of the Advanced Radiotherapy Platform Over a 20-Year Timeframe SUNNYVALE, Calif. , Nov. 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that more than two
Toggle Summary Accuray To Participate at Stifel 2021 Virtual Healthcare Conference
Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) today announced its participation in Stifel's 2021 Virtual Healthcare Conference . The management team is scheduled to present on
Toggle Summary Accuray Reports Fiscal 2022 First Quarter Financial Results
Record Revenue First Quarter Fiscal 2022 SUNNYVALE, Calif. , Nov. 3, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 .     First Quarter Fiscal 2022 Summary Record net revenue of $107.4 million
Toggle Summary Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
SUNNYVALE, Calif. , Oct. 25, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology  found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.